A Cyber "Warhead" With an Unknown Target
The Gauss malware described last week that targets Lebanese bank accounts still has one secret to divulge - the purpose of its “encrypted warhead” known as Godel. That’s the term used by researchers at Kaspersky, the computer security firm that described Gauss last week, for a part of the malware programmed to decrypt only when it lands on exactly the right computer system. What Godel does under those conditions is unknown, and today, Kaspersky laid out what it knows about Godel and asked for help determining its purpose.

[T]oday we are presenting all the available information about the payload in the hope that someone can find a solution and unlock its secrets. We are asking anyone interested in cryptology and mathematics to join us in solving the mystery and extracting the hidden payload.
Kaspersky says Gauss is related to government-sponsored cyberweapons Stuxnet and Flame, and the company’s researchers and some other experts believe Gauss was also created by a nation state. Godel can only be decrypted with a key built using information drawn from the computer it has infected, specifically information about programs installed on the system. Until someone figures out exactly what Godel’s looking for, it’s impossible to know what it will do when activated. Kaspersky’s researchers are considering the possibility that it is intended to attack SCADA - industrial control - systems, like those in use by the Iranian nuclear program disrupted by Stuxnet:
The resource section is big enough to contain a Stuxnet-like SCADA targeted attack code and all the precautions used by the authors indicate that the target is indeed high profile.
Keep Reading
Most Popular

Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.